Unveiled abstracts from Asco lift the stock of several biotechs, which will now be under pressure not to disappoint at the conference next week.
The preclinical company pulled off a giant flotation, and though its stock has since slumped it now has several years’ cash to play with.
At a conference largely focused on big biopharma a few biotech catalysts stand out.
A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.
And four other potential targets that could make sense for the beleaguered group.